Autolus Therapeutics to Present Preclinical Data on AUT06NG at the SITC Annual Meeting

5th November 2019

Poster presentation will highlight preclinical data regarding feasibility, safety, and efficacy for AUTO6NG in solid tumor indication

LONDON, UK, November 5, 2019 -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies for the treatment of cancer, announced today pre-clinical data on AUTO6NG, the company’s next generation GD2-targeting CAR T cell therapy, at the 34th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) being held November 6-10, 2019, in Washington, D.C. SITC published the abstract today, which can be found at :

https://sitc.planion.com/Web.User/AbstractDet?ACCOUNT=SITC&ABSID=12038&CONF=SITC19&ssoOverride=OFF&CKEY=

“AUTO6NG builds on the clinically active AUTO6 GD2-targeting CAR and adds cell programming modules to improve persistence and render the product insensitive to several tumor defense mechanisms. This is the first program presentation illustrating our suite of advanced cell programming technologies.”

Dr Christian Itin, chairman and chief executive officer of Autolus

Poster Presentation

Abstract #: P146

Abstract Title: “AUTO6NG: Next generation GD2-targeting CAR T-cell therapy with improved persistence and insensitivity to TGFBeta and checkpoint inhibition for relapsed/refractory neuroblastoma”, Achkova, D., et al.

Session Date: Saturday, November 9

Session Time: Posters on display 7:00 am – 8:30 pm Eastern Time; author(s) will be at poster 12:35 – 2:05 p.m. and also during the poster reception 7 – 8:30 p.m.

About AUTO6NG

AUTO6NG is a next generation programmed T cell product candidate in pre-clinical development. AUTO6NG builds on preliminary proof of concept data from AUTO6, a CAR in clinical development for the treatment of neuroblastoma, which can target GD2-expressing cancers with a chimeric antigen receptor (CAR). AUTO6NG incorporates additional cell programming modules to augment its functions by extending persistence and rendering modified T-cells resistant to immune inhibition. With the enhanced properties of AUTO6NG, it may be suitable for the treatment of GD2-expressing solid tumors, including neuroblastoma, osteosarcoma, melanoma, small cell lung cancer, and soft tissue sarcoma.

AUTO6 is currently in a Phase 1 clinical trial for pediatric neuroblastoma conducted by Cancer Research UK in collaboration with University College London. Autolus has worldwide commercial rights to the GD2-targeting programmed T cell product candidate.